MX357491B - Co-diferenciacion de los monocitos a partir de donantes alogenicos. - Google Patents
Co-diferenciacion de los monocitos a partir de donantes alogenicos.Info
- Publication number
- MX357491B MX357491B MX2015007800A MX2015007800A MX357491B MX 357491 B MX357491 B MX 357491B MX 2015007800 A MX2015007800 A MX 2015007800A MX 2015007800 A MX2015007800 A MX 2015007800A MX 357491 B MX357491 B MX 357491B
- Authority
- MX
- Mexico
- Prior art keywords
- allogeneic
- monocytes
- differentiation
- allogeneic donors
- donors
- Prior art date
Links
- 230000000735 allogeneic effect Effects 0.000 title abstract 8
- 210000001616 monocyte Anatomy 0.000 title abstract 3
- 210000004443 dendritic cell Anatomy 0.000 abstract 3
- 210000000265 leukocyte Anatomy 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides or bases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
- C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un método de producción de células dendríticas inmaduras no agotadas (DCs) procedentes de dos diferentes donantes alogénicos. En el método, se proporciona una mezcla de leucocitos alogénicos, cuyos leucocitos alogénicos han sido obtenidos a partir de al menos dos donantes alogénicos diferentes. Posteriormente, los monocitos alogénicos se aíslan de la mezcla de leucocitos alogénicos. A partir de entonces, las DCs inmaduras no agotadas se generan a partir de dicho monocitos alogénicos aisladas. Un método de producción de DCs pro-inflamatorias, que comprende las etapas de: proporcionar DCs inmadura no agotadas, activar las DCs inmaduras no agotadas para obtener DCs pro-inflamatorias.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12197687 | 2012-12-18 | ||
| PCT/EP2013/077139 WO2014096033A1 (en) | 2012-12-18 | 2013-12-18 | Co-differentiation of monocytes from allogeneic donors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015007800A MX2015007800A (es) | 2016-01-12 |
| MX357491B true MX357491B (es) | 2018-07-11 |
Family
ID=47427250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015007800A MX357491B (es) | 2012-12-18 | 2013-12-18 | Co-diferenciacion de los monocitos a partir de donantes alogenicos. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9714413B2 (es) |
| EP (2) | EP2788474B1 (es) |
| JP (1) | JP6529439B2 (es) |
| KR (1) | KR102148051B1 (es) |
| CN (2) | CN105452449B (es) |
| AU (1) | AU2013360793B2 (es) |
| BR (1) | BR112015014270B1 (es) |
| CA (1) | CA2895280C (es) |
| DK (2) | DK2788474T3 (es) |
| ES (2) | ES2591230T3 (es) |
| HU (2) | HUE028895T2 (es) |
| MX (1) | MX357491B (es) |
| PL (2) | PL2788474T3 (es) |
| RU (1) | RU2668816C2 (es) |
| SI (2) | SI2788474T1 (es) |
| WO (1) | WO2014096033A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3460052B1 (en) | 2017-09-20 | 2019-10-30 | Immunicum AB | Improved allogeneic dendritic cells for use in cancer treatment |
| US20200338173A1 (en) * | 2018-01-18 | 2020-10-29 | University Of South Florida | Dead antigen stimulated immature heterogenous dendritic cells as therapeutics for diseases |
| CN108660125A (zh) * | 2018-05-14 | 2018-10-16 | 武汉博百欧生物科技有限公司 | 一种从人体输血废弃物中提取中性粒细胞嗜天青颗粒的方法 |
| US20220106566A1 (en) * | 2019-01-22 | 2022-04-07 | The Brigham And Women`S Hospital, Inc. | Antigen-Presenting Neutrophil-Derived Dendritic Cells and Methods of Use Thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1259592A1 (en) * | 2000-01-11 | 2002-11-27 | Maxygen, Inc. | Monocyte-derived dendritic cell subsets |
| WO2003010292A2 (en) * | 2001-07-25 | 2003-02-06 | Northwest Biotherapeutics, Inc. | Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors |
| SI1509244T1 (sl) | 2002-06-06 | 2011-11-30 | Immunicum An | Nov postopek in spojina za izdelavo celične alogenične vakcine |
| KR100585456B1 (ko) * | 2003-09-30 | 2006-06-07 | 국립암센터 | 동종 종양-관련 항원이 탑재된 수지상세포, 이의 제조방법및 이를 유효성분으로 하는 암 치료용 백신 조성물 |
| CA2504451A1 (en) * | 2004-08-10 | 2006-02-10 | Geron Corporation | Dendritic cell vaccines for treating cancer made from embryonic stem cells |
| CN103589684A (zh) * | 2005-12-08 | 2014-02-19 | 西北生物治疗药物公司 | 用于诱导未成熟单核细胞的树突细胞的激活的组合物和方法 |
| EP1806395A1 (en) * | 2006-01-06 | 2007-07-11 | Stichting Sanquin Bloedvoorziening | Maturation of dendritic cells |
| EP1840206A1 (en) * | 2006-03-28 | 2007-10-03 | Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh | Compositions for the preparation of mature dendritic cells |
| CN102597222B (zh) * | 2009-10-27 | 2015-07-15 | 因缪尼卡姆股份公司 | 用于增殖抗原特异性t细胞的方法 |
| JP5855018B2 (ja) * | 2010-02-10 | 2016-02-09 | イミュニカム アーベー | 腫瘍細胞増殖を阻害するための改善された組成物 |
| EP2696894B1 (en) * | 2011-04-13 | 2017-11-01 | Immunicum AB | Method for priming of t cells |
| WO2012140130A1 (en) * | 2011-04-13 | 2012-10-18 | Immunicum Ab | Method for proliferation of antigen-specific t cells |
-
2013
- 2013-12-18 CA CA2895280A patent/CA2895280C/en active Active
- 2013-12-18 WO PCT/EP2013/077139 patent/WO2014096033A1/en active Application Filing
- 2013-12-18 DK DK13814106.4T patent/DK2788474T3/en active
- 2013-12-18 CN CN201380066722.0A patent/CN105452449B/zh active Active
- 2013-12-18 PL PL13814106T patent/PL2788474T3/pl unknown
- 2013-12-18 KR KR1020157015766A patent/KR102148051B1/ko active IP Right Grant
- 2013-12-18 DK DK15161369.2T patent/DK2913394T3/en active
- 2013-12-18 EP EP13814106.4A patent/EP2788474B1/en active Active
- 2013-12-18 HU HUE15161369A patent/HUE028895T2/en unknown
- 2013-12-18 SI SI201330066T patent/SI2788474T1/sl unknown
- 2013-12-18 HU HUE13814106A patent/HUE027619T2/en unknown
- 2013-12-18 PL PL15161369.2T patent/PL2913394T3/pl unknown
- 2013-12-18 AU AU2013360793A patent/AU2013360793B2/en active Active
- 2013-12-18 CN CN201910284719.5A patent/CN110042081B/zh active Active
- 2013-12-18 ES ES15161369.2T patent/ES2591230T3/es active Active
- 2013-12-18 SI SI201330281A patent/SI2913394T1/sl unknown
- 2013-12-18 RU RU2015119164A patent/RU2668816C2/ru active
- 2013-12-18 JP JP2015547082A patent/JP6529439B2/ja active Active
- 2013-12-18 US US14/653,184 patent/US9714413B2/en active Active
- 2013-12-18 EP EP15161369.2A patent/EP2913394B1/en active Active
- 2013-12-18 BR BR112015014270-2A patent/BR112015014270B1/pt not_active IP Right Cessation
- 2013-12-18 MX MX2015007800A patent/MX357491B/es active IP Right Grant
- 2013-12-18 ES ES13814106.4T patent/ES2548229T3/es active Active
-
2017
- 2017-06-15 US US15/623,530 patent/US10626371B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020201465A1 (en) | Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing | |
| PH12014502010A1 (en) | Bispecific antibodies against human tweak and human il17 and uses thereof | |
| MX2022007800A (es) | Anticuerpos anti-gen de activacion de linfocitos gen-3 (lag-3) para usarse en el tratamiento de neoplasias hematologicas. | |
| MX2017007538A (es) | Sintesis de ácido nucleíco de volúmen pequeño, alta eficiencia. | |
| MX2015015395A (es) | Celulas solares mesoscopicas sensibilizadas con perovskita de alto rendimiento. | |
| PH12015500040A1 (en) | Supercritical hydrolysis of biomass | |
| EA201390039A1 (ru) | Способ разделения газов | |
| IN2014CN04160A (es) | ||
| EA201491195A1 (ru) | Способ получения композиции, содержащей галактоолигосахариды | |
| MX2014002996A (es) | Anticuerpos anti - egfr/anti - igf-1r bisespecificos. | |
| MX2018006489A (es) | Nanoemulsiones para bebidas producidas mediante un proceso de alto cizallamiento. | |
| MX366112B (es) | Medio de cultivo celular y metodos de produccion de anticuerpos. | |
| UA109154C2 (uk) | Спосіб відокремлення інбредного насіння і машина для його здійснення | |
| EP3353287A4 (en) | COMPOSITIONS AND METHODS FOR PRODUCING DENDRITIC CELLS | |
| MX2016015893A (es) | Produccion de fragmentos de fragmento cristalizable (fc). | |
| MX2015007800A (es) | Co-diferenciacion de los monocitos a partir de donantes alogenicos. | |
| IN2014DN08412A (es) | ||
| WO2016033437A3 (en) | Polyethers, polyamines, polythioethers, and methods for making same | |
| MY177641A (en) | Process for the preparation of hexachlorodisilane by cleavage of higher polychlorosilane such as octachlorotrisilane | |
| MX2016006976A (es) | Proceso para la preparacion de 5-fluoro-1h-pirazoles. | |
| MX2016013897A (es) | Proceso de produccion de gasolina que comprende una etapa de isomerizacion seguida de al menos dos etapas de separacion. | |
| MX352837B (es) | Método para marcaje de objetivos intracelulares y extracelulares de leucocitos. | |
| GEP201706626B (en) | Synthesis of (s)-nifuratel | |
| PH12015501636B1 (en) | Method for preparing 1-(4-(4-(3,4 - dichloro -2- fluorophenylamino)-7- methoxyquinazolin -6- yloxy) piperidin -1-yl) prop-2-en-1-one | |
| WO2015100160A3 (en) | Transgenic production of heparin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |